NephroDI Therapeutics, Inc. — Form D
NephroDI Therapeutics, Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2024-06-18. The offering totals $4.0M, of which $2.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2024-06-18
- Form: D
- Accession: 0001840655-24-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $4.0M
- Amount sold: $2.0M
- Remaining: $2.0M
- Investors: 2
- Date of first sale: 2024-06-11
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-516337
Issuer
- Name: NephroDI Therapeutics, Inc.
- CIK: 0001840655
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 2200 32ND AVE W, SEATTLE, WA, 98199
- Phone: 206-696-0546
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Michael Grissinger | Director | Seattle, WA |
| Rachael Hagan | Director | Seattle, WA |
| Bibhash M Mukhopadhyay | Director | Seattle, WA |
| Rachael Hagan | Executive Officer | Seattle, WA |
| Jeff M Sands, M.D. | Executive Officer | Seattle, WA |
| Fred M Callori | Director | Philadelphia, PA |
| Chris M Garabedian | Director | Philadelphia, PA |
| Donna M See | Director | Philadelphia, PA |
Other filings by this issuer (1)
More